In this video interview, Umesh Chaudhari, executive medical director and global program head of the C5 programs at Regeneron, ...

Panelists discuss how the BE OPTIMAL study enrolled biologic-naive patients, whereas BE COMPLETE enrolled TNF inhibitor-inadequate responders. Both populations showed similar response rates despite ...

Oruka Therapeutics presents positive interim phase 1 results for ORKA-001 at EADV Congress: Menlo Park, California Thursday, September 18, 2025, 18:00 Hrs [IST] Oruka Therapeutics ...

The Company plans to use the proceeds to accelerate the development of Teverelix, a next generation GnRH Antagonist, as a ...

In total, 59% of abstracts that were submitted in 2022 were improved after peer review as deemed by blinded independent ...

HOUSTON -- Survival in untreated, intermediate- and higher-risk myelodysplastic syndromes (MDS) failed to improve with the addition of the targeted agent venetoclax (Venclexta) to chemotherapy, a ...

EVERLAST-A Phase 2a trial enrollment ongoing with data expected 2H 2026 MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology ...

Researchers executed a phase 1b study to determine the safety and efficacy of venetoclax combined with a 7+3 chemotherapy regimen in treating acute myeloid leukemia.

A new randomized controlled trial protocol from the Netherlands will test whether altering the texture, and thus the eating ...

Cardiopulmonary POCUS using devices that attach to smartphones shortened hospital stays and reduced costs for patients ...